论文部分内容阅读
Objective: Most non-small cell lung cancer(NSCLC)patients responding to gefitinib harbor activating mu tations in the epidermal growth factor receptor(EGFR).Acquired resistance to gefitinib can occur through T790M mutation in EGFR or bypass signals.Besides,K-ras mutations were identified as the primary resistance to gefitinib.We investigated whether Capilliposide(CPS),extracted from Lysimachia capillipes Hemsl,combined with gefitinib could overcome the resistance of NSCLC to gefitinib.